Advanced search
Publication Cover
Biotechnology & Biotechnological Equipment Volume 35, 2021 - Issue 1
Submit an article Journal homepage
1,053
Views
0
CrossRef citations to date
0
Altmetric
Articles

Molecular response in long-term monitoring of patients with chronic myelogenic leukemia (CML) on nilotinib therapy

Dragomira Nikolovaa Department of Medical Genetics, Faculty of Medicine, Medical University of Sofia, Sofia, Bulgaria;b Genetic Laboratory, University Hospital “St.Ivan Rilski”, Sofia, BulgariaCorrespondence[email protected]
,
Vera Damyanovaa Department of Medical Genetics, Faculty of Medicine, Medical University of Sofia, Sofia, Bulgaria;b Genetic Laboratory, University Hospital “St.Ivan Rilski”, Sofia, Bulgaria
,
Atanas Radinovc Clinic of Hematology, University Hospital “St.Ivan Rilski”, Sofia, Bulgaria
&
Draga Tonchevaa Department of Medical Genetics, Faculty of Medicine, Medical University of Sofia, Sofia, Bulgaria
Pages 650-656 | Received 15 Oct 2020, Accepted 26 Mar 2021, Published online: 01 May 2021

References

  • Branford S, Hughes T. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med. 2006;125:93–106.
  • Assouline S, Lipton JH. Monitoring response and resistance to treatment in chronic myeloid leukemia. Curr Oncol. 2011;18(2):e71–e83.
  • Hochhaus A, Krei S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16(11):2190–2196.
  • Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408–2417.
  • de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26(20):3358–3363.
  • Blay JY, von Mehren M. Nilotinib: a novel, selective tyrosine kinase inhibitor. Semin Oncol. 2011;38 Suppl 1(Suppl 1(0 1):S3–S9.
  • Kantarjian H, Talpaz M, O’Brien S, et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia–comparison with historic experience. Cancer. 2005;103(10):2099–2108.
  • Weisberg E, Manley P, Mestan J, et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006;94(12):1765–1769.
  • O’Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500–4505.
  • Kuo CY, Wang PN, Hwang WL, et al. Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study. Ther Adv Hematol. 2018;9(3):65–78.
  • Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540–3546.
  • Eghtedar A, Kantarjian HJ, O’Brien E, et al. Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013;13(4):477–484.
  • Hochhaus A, Saglio M, García-Gutiérrez G, et al. Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors . Leukemia. 2020;34(6):1495–1502.
  • Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia. 2003;17(12):2474–2486.
  • Nikolova D, Damyanova V, Hrischev V, et al. Philadelphia-positive case negative for JAK2 V617F mutation with hyperdiploidic karyotype: a case report. Mol Clin Oncol. 2019;11(6):607–611.
  • Branford S, Cross NC, Hochhaus A, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia. 2006; 20(11):1925–1930.
  • Jobbagy Z, van Atta R, Murphy KM, et al. Evaluation of the Cepheid GeneXpert BCR-ABL assay. J Mol Diagn. 2007;9(2):220–227.
  • Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28–37.
  • Hughes T. ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring. Hematology Am Soc Hematol Educ Program. 2006;2006(1):211–218.
  • Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26(10):2197–2203.
  • Wang L, Pearson K, Ferguson JE, et al. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol. 2003;120(6):990–999.
  • Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–1054.
  • Cepheid Xpert BCR-ABL Ultra Package Insert 301-2194. 2021.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.